Premium
Idiopathic thrombocytopenic purpura (ITP) in children
Author(s) -
Baronci Carlo,
Pansini Valeria,
Funaro Daria,
Coletti Valentina,
Caruso Roberta,
Rossi Giulio De
Publication year - 2006
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.20998
Subject(s) - medicine , thrombocytopenic purpura , methylprednisolone , platelet , dexamethasone , blood cancer , pediatrics , purpura (gastropod) , gastroenterology , surgery , cancer , biology , ecology
Idiopathic thrombocytopenic purpura in children remits spontaneously in the majority of cases but most children require treatment. Between 1995 and 2005, 265 children (0–15 years old) have been consecutively observed and treated: 28 children with high doses of methylprednisolone (HDMP) (15 mg/kg × 4 days), 63 with HDMP (7.5 mg/kg × 4 days), 37 with HD dexamethasone (DXM) pulses, 29 with low doses of MP, and 51 with different doses of intravenous immunoglobulins (IVIG) (0.4 or 0.8 g/kg). Fifty‐seven children have not been treated because of a platelet count ≥10 × 10 9 /L and no significant bleeding. Two hundred forty‐four (92.1%) children reached a persistent CR, 237 (89.4%) after a first‐line treatment or the wait and see strategy. No statistically significant differences in CR related to different treatments have been observed. IVIG and HDMP (7.5 mg/kg for 4 days) are the best treatments to reach quickly safe platelet levels ≥30 × 10 9 /L (3–6 days) and CR (7–11 days). Among non‐responding (NR) patients, seven have been splenectomized and three reached stable CR. These results emphasize differences with adult ITP. Pediatr Blood Cancer 2006;47:665–667. © 2006 Wiley‐Liss, Inc.